EE696 Decision Model to Evaluate the Cost of Clinical Events Associated With Switching From Apixaban to Rivaroxaban Among Patients With Non-Valvular Atrial Fibrillation in Greece
Abstract
Authors
A Solakidi M Barmpouni D Trafalis Ι Antoniou C Tzanetakos G Gourzoulidis